Steinberg E H, Madmon L, Patel C P, Sedlis S P, Kronzon I, Cohen J L
Department of Cardiology, New York Veterans Affairs Medical Center/New York University School of Medicine, New York 10010, USA.
J Am Coll Cardiol. 1997 Apr;29(5):969-73. doi: 10.1016/s0735-1097(97)00032-6.
This study sought to assess the long-term prognostic utility of dobutamine stress echocardiography in predicting fatal and nonfatal cardiac events.
Although dobutamine stress echocardiography has improved sensitivity and specificity for detection of coronary artery disease, little is known of its predictive value for long-term cardiac events. Therefore, we followed up 120 consecutive patients who underwent dobutamine echocardiography for suspected coronary disease from March 1989 to August 1991.
All patients presenting for coronary angiography for chest pain were eligible for recruitment. Follow-up was 100% complete at 5 years (range 3.0 to 6.1). Cardiac events were defined as cardiac death or nonfatal myocardial infarction or the need for coronary revascularization (coronary angioplasty or bypass surgery).
Positive (n = 78) and negative (n = 42) dobutamine test groups differed in their rates of coronary artery bypass graft surgery (37.2% vs. 9.5%, p < 0.001, respectively) and mortality. Of 26 total deaths, 22 occurred in the group with positive dobutamine test results (28% vs. 9.5%, p < 0.018); all 7 cardiac deaths occurred in this group as well (9% vs. 0%, p < 0.045). By multivariate regression analysis, positive results on dobutamine echocardiography remained independently predictive of future cardiac death after left ventricular ejection fraction and other clinical variables were accounted for.
A positive finding on dobutamine echocardiography is an independent predictor of long-term cardiac mortality, whereas a negative finding confers a significantly reduced likelihood of cardiac death as much as 5 years from initial testing. We conclude that dobutamine stress echocardiography can be used to predict which patients with suspected coronary artery disease are at low risk for cardiac death and do not require concurrent nuclear or invasive testing.
本研究旨在评估多巴酚丁胺负荷超声心动图在预测致命性和非致命性心脏事件方面的长期预后效用。
尽管多巴酚丁胺负荷超声心动图在检测冠状动脉疾病方面提高了敏感性和特异性,但其对长期心脏事件的预测价值却知之甚少。因此,我们对1989年3月至1991年8月间因疑似冠心病接受多巴酚丁胺超声心动图检查的120例连续患者进行了随访。
所有因胸痛进行冠状动脉造影的患者均符合入选标准。5年时随访完成率为100%(范围3.0至6.1年)。心脏事件定义为心源性死亡、非致命性心肌梗死或需要进行冠状动脉血运重建(冠状动脉成形术或搭桥手术)。
多巴酚丁胺试验阳性组(n = 78)和阴性组(n = 42)在冠状动脉搭桥手术率(分别为37.2%对9.5%,p < 0.001)和死亡率方面存在差异。在总共26例死亡病例中,22例发生在多巴酚丁胺试验结果阳性组(28%对9.5%,p < 0.018);所有7例心源性死亡也都发生在该组(9%对0%,p < 0.045)。通过多因素回归分析,在考虑左心室射血分数和其他临床变量后,多巴酚丁胺超声心动图阳性结果仍然是未来心源性死亡的独立预测因素。
多巴酚丁胺超声心动图检查结果阳性是长期心脏死亡率的独立预测因素,而阴性结果则使自初始检查起长达5年内心脏死亡的可能性显著降低。我们得出结论,多巴酚丁胺负荷超声心动图可用于预测哪些疑似冠状动脉疾病患者心脏死亡风险较低,且无需同时进行核素或侵入性检查。